Log In Sign up
The largest database of trusted experimental protocols
> Disorders > Neoplastic Process > Carcinoma, Large Cell

Carcinoma, Large Cell

Carcinoma, Large Cell: A type of non-small cell lung cancer characterized by large, undifferentiated cells with abundant cytoplasm and vesicular nuclei.
This aggressive form of lung cancer can arise de novo or transform from other non-small cell lung cancer subtypes.
Prompt diagnosis and appropriate treatment are crucial for managing this condition and improving patient outcomes.

Most cited protocols related to «Carcinoma, Large Cell»

1
Lung Cancer Trends by Histology and Smoking
Cited 13 times
SEER data were used to analyze trends among whites and blacks during 1977 to 2010 in the nine original registries of Atlanta, Connecticut, Detroit, Hawaii, Iowa, New Mexico, San Francisco-Oakland, Seattle-Puget Sound, and Utah [9 ], and among white non-Hispanics, Asian/PIs and Hispanic whites in the 13 registries: the SEER9 registries plus Los Angeles, San Jose-Monterey, rural Georgia, and Alaska Natives during 1992–2010 [10 ].
Site recode in SEER*stat software version 8.1.2[11 ] was used to select microscopically-confirmed lung and bronchus cancer cases. Histologic groupings were created using ICD-O-3 [12 ] morphology codes. Six main histologic type categories were formed: squamous cell carcinoma, small cell carcinoma, adenocarcinoma, large cell carcinoma, other specified carcinoma, and unspecified types. The morphology codes were: squamous cell carcinoma (8051-2, 8070-6, 8078, 8083-4, 8090, 8094, 8120, 8123); small cell carcinoma (8002, 8041-5); adenocarcinoma (8015, 8050, 8140-1, 8143-5, 8147, 8190, 8201, 8211, 8250-5, 8260, 8290, 8310, 8320, 8323, 8333, 8401, 8440, 8470-1, 8480-1, 8490, 8503, 8507, 8550, 8570-2, 8574, 8576); large cell carcinoma (8012-4, 8021, 8034, 8082); other specified carcinoma (8003-4, 8022, 8030-3, 8035, 8200, 8240-1, 8243-6, 8249, 8430, 8525, 8560, 8562, 8575); and unspecified malignant neoplasms (carcinoma not otherwise specified [NOS] 8010-1, 8020, 8230; non-small cell carcinoma 8046 ; malignant neoplasm NOS 8000-1). We omitted cases specified as a non-carcinoma (8580-9999) or that appeared to be a metastasis (8005, 8095, 8124, 8130, 8146, 8160, 8170, 8231, 8247, 8263, 8312, 8340-1, 8350, 8370, 8441, 8460, 8500, 8501, 8510, 8524, 8530, 8551). A code for non-small cell carcinoma (8046) was added to ICD-O-3 in 2001, which was also used for some cases diagnosed prior to 2001.
We calculated incidence counts, rates per 100,000 person-years, rate ratios (IRRs) and 95% CIs by histologic type, period, gender, racial/ethnic group, and 5-year age group. Rates were age-adjusted using the 2000 US standard for all ages combined and for 10-year age groups 25–34 to 75–84 and 85+ years for calendar years 1977–1981, 1982–1986, 1987–1991, 1992–1996, 1997–2000, 2001–2005, and 2006–2010, with each 5 years except for the 4-year interval 1997–2000 to allow assessment of the change to ICD-O-3 in 2001. Year of birth was estimated by subtracting the age group mid-year from the diagnosis period mid-year. All rates were plotted using the period mid-year and a semi-logarithmic scale such that a change of 1% per year was depicted by a slope of 10 degrees [13 (link)], achieved by having one y-axis log cycle the same length as 40 years on the x-axis.
The prevalence of ever smoking at age 35 by year of birth through 1950–54 was available from 1885–89 for whites and from 1900–04 for blacks in the Smoking and Tobacco Control Monograph 8 [14 ]. More recent ever smoking data for the age group 35–44 were based on National Health Interview Data for each 5th year 1990–2010 [15 ]. The prevalence of current cigarette smoking aged 18 and older by race/ethnicity and sex were from several National Health Interview Surveys [16 ]. Rates among whites and blacks were from surveys conducted every 5 years 1965 – 2005 and 2008, 2009, and 2010, with rates for the three years averaged and plotted at their mid-point, 2009.5. Asian and Hispanic rates were for 3-year period averages, 1990–1992, 1999–2001, and 2008–2010. Rates were not readily available for ever smoking among Asians or Hispanics or current smoking among Asians. Temporal trends in ever and current smoking prevalence were plotted as were the incidence rates, so that the slopes of the curves are comparable [13 (link)].
Lewis D.R., Check D.P., Caporaso N.E., Travis W.D, & Devesa S.S. (2014). U.S. Lung Cancer Trends by Histologic Type. Cancer, 120(18), 2883-2892.
Publication 2014
Adenocarcinoma Age Groups Alaskan Natives Asian Persons Birth Bronchogenic Carcinoma Carcinoma Carcinoma, Large Cell Carcinoma, Small Cell Diagnosis Epistropheus Ethnicity Hispanics INSRR protein, human Lung Malignant Neoplasms Negroes Neoplasm Metastasis Racial Groups Sound Squamous Cell Carcinoma White Person
2
Meta-Analysis of Lung Cancer GWAS
Cited 12 times
Associations between SNP genotypes and lung cancer risk were evaluated under a log-additive model of inheritance. Additionally, we explored dominant, recessive and co-dominant models. Each study center provided summary statistics from two models: (i) unconditional logistic regression adjusted for sex, age at diagnosis or age at recruitment (5-year age intervals), country/study center where appropriate and significant principal components for population stratification and (ii) additionally adjusted for smoking status coded as categorical variable never/current/former. Analyses stratified by histology (adenocarcinoma, squamous cell carcinoma, large-cell carcinoma and small-cell carcinoma), sex, age at diagnosis for cases or recruitment for controls (≤50 and >50 years), smoking status (current, former, never), tumor stage (I–IV) and family history of lung cancer in a first-degree relative were performed (Supplementary Material, Table S1). Both the UK studies did not contribute data to the smoking analysis, since this information was not available for controls. In addition to the above analyses, each centre provided lung cancer risk estimates for 15q25, 6p21 and 5p15 loci after controlling for allelic dosage for the most significantly associated SNP(s) within the locus. For the 15q25 locus, the statistical model included rs1051730 and/or rs6495309 allelic dosages as covariates; for the 6p21 locus, rs3117582 allelic dosage and for the 5p15 locus allelic, dosages for rs401681 and/or rs2736100.
Prior to undertaking the meta-analysis of all GWAS data sets, we searched for potential errors and biases in data from each case–control series (82 (link)). With the exception of the Liverpool Lung Project, quantile–quantile (Q–Q) plots showed that there was minimal inflation of the test statistics, indicating that substantial cryptic population substructure or differential genotype calling between cases and controls was unlikely in each of the GWASs (Supplementary Material, Fig. S1).
Timofeeva M.N., Hung R.J., Rafnar T., Christiani D.C., Field J.K., Bickeböller H., Risch A., McKay J.D., Wang Y., Dai J., Gaborieau V., McLaughlin J., Brenner D., Narod S.A., Caporaso N.E., Albanes D., Thun M., Eisen T., Wichmann H.E., Rosenberger A., Han Y., Chen W., Zhu D., Spitz M., Wu X., Pande M., Zhao Y., Zaridze D., Szeszenia-Dabrowska N., Lissowska J., Rudnai P., Fabianova E., Mates D., Bencko V., Foretova L., Janout V., Krokan H.E., Gabrielsen M.E., Skorpen F., Vatten L., Njølstad I., Chen C., Goodman G., Lathrop M., Benhamou S., Vooder T., Välk K., Nelis M., Metspalu A., Raji O., Chen Y., Gosney J., Liloglou T., Muley T., Dienemann H., Thorleifsson G., Shen H., Stefansson K., Brennan P., Amos C.I., Houlston R, & Landi M.T. (2012). Influence of common genetic variation on lung cancer risk: meta-analysis of 14 900 cases and 29 485 controls. Human Molecular Genetics, 21(22), 4980-4995.
Publication 2012
Adenocarcinoma Alleles Carcinoma, Large Cell Carcinoma, Small Cell CFC1 protein, human Diagnosis Genome-Wide Association Study Genotype Lung Lung Cancer Neoplasms Pattern, Inheritance Squamous Cell Carcinoma
3
Lung Adenocarcinoma Tissue Collection Protocol
Cited 12 times
The Early Detection Research Network (EDRN)/Canary Foundation tissue collection consisted of 60 lung adenocarcinoma tumors and matched adjacent histologically confirmed non-tumor lung (NTL), collected after surgery. Forty-five adenocarcinoma/NTL pairs were obtained from the Vancouver General Hospital (Vancouver, Canada) and 15 adenocarcinoma/NTL pairs from the British Columbia Cancer Agency Tumor Tissue Repository (Vancouver, Canada, BCCA Research Ethics Board #H09-00008). Thirty subjects were never-smokers (defined as less than 100 lifetime cigarettes), and 30 were current smokers (average 53 pack-years, range 11–120 pack-years). One tumor sample was excluded after pathology review later revealed it to be a large cell carcinoma. Subject characteristics for the remaining 59 subjects are detailed in Table 1. For verification of DNA methylation profiling, an independent sample set of 28 lung adenocarcinomas and 27 NTL was used. Subject characteristics for the validation population are detailed in Supplemental Table 2. Of these, 21 tumor and 20 NTL de-identified samples were purchased from the Ontario Tumor Bank (OTB, Ontario, Canada), while seven tumors and seven NTL were collected at the University Hospital at the University of Southern California (USC IRB protocol #HS-06-00447). For MethyLight verification of selected probes, OTB samples were used (26 tumors and 26 NTL), of which 25 pairs were matched. Ten of the tumors and 13 of the NTL samples examined by MethyLight were the same tissues used for the genome-wide verification. EDRN/Canary samples were assessed by an experienced pathologist (A.F.G.), while the verification samples were assessed by a separate expert lung pathologist (M.N.K.). All sample collections were performed conforming to protocols approved by the appropriate local Institutional Review Boards and were acquired with informed consent. The identities of the subjects were not made available to the laboratory investigators.
Selamat S.A., Chung B.S., Girard L., Zhang W., Zhang Y., Campan M., Siegmund K.D., Koss M.N., Hagen J.A., Lam W.L., Lam S., Gazdar A.F, & Laird-Offringa I.A. (2012). Genome-scale analysis of DNA methylation in lung adenocarcinoma and integration with mRNA expression. Genome Research, 22(7), 1197-1211.
Publication 2012
Adenocarcinoma of Lung Carcinoma, Large Cell DNA Methylation Early Diagnosis Ethics Committees, Research Genome Lung Lung Neoplasms Malignant Neoplasms Neoplasms Operative Surgical Procedures Pathologists Serinus Specimen Collection Tissues
4
Molecular Characterization of Prostate Cancer
Cited 10 times
Tumor specimens were obtained prospectively through clinical protocols approved by the Weill Cornell Medicine (WCM) Institutional Review Board (IRB) with informed consent (IRB #1305013903, #1210013164) or retrospectively (IRB #0905010441) and germline DNA obtained from either peripheral blood mononuclear cells (PBMCs) or benign tissue. The total number of subjects enrolled in this study was 81, all of male gender; no blinding, randomization, or exclusion criteria were used. All fresh/frozen tissues were processed as previously described26 (link),52 (link). All hematoxylin and eosin stained slides were reviewed by board-certified pathologists (J.M.M., M.A.R.). Tumors were classified based on histomorphology as adenocarcinoma (A) or CRPC-NE (B-E) based on a published pathologic classification system8 (link) (Supplementary Fig. 1). Category A represents usual prostate adenocarcinoma without neuroendocrine differentiation, Category B represents usual prostate adenocarcinoma with neuroendocrine differentiation > 20%, Category C represents small cell carcinoma, Category D represents large cell neuroendocrine carcinoma, and Category E represents mixed small cell carcinoma – adenocarcinoma. Clinical and pathologic features of the cohort are summarized in Supplementary Table 1 and Supplementary Fig. 1.
Beltran H., Prandi D., Mosquera J.M., Benelli M., Puca L., Cyrta J., Marotz C., Giannopoulou E., Chakravarthi B.V., Varambally S., Tomlins S.A., Nanus D.M., Tagawa S.T., Van Allen E.M., Elemento O., Sboner A., Garraway L.A., Rubin M.A, & Demichelis F. (2016). Divergent clonal evolution of castration resistant neuroendocrine prostate cancer. Nature medicine, 22(3), 298-305.
Publication 2016
Adenocarcinoma Carcinoma, Large Cell Carcinoma, Small Cell Clinical Protocols Eosin Ethics Committees, Research Freezing Germ Line Hematoxylin Males Neoplasms Neurosecretory Systems Pathologists PBMC Peripheral Blood Mononuclear Cells Pharmaceutical Preparations Prostate Tissues
5
Cytotoxicity Screening of Compounds
Cited 8 times
The cytotoxicity measurements against the MCF-725 (link) human breast carcinoma (Barbara A. Karmanos Cancer Center), NCI-H46026 (link) human large cell lung carcinoma (HTB-177, American Type Culture Collection (ATCC), and SF-26827 (link) human astrocytoma (NCI Developmental Therapeutics Program) cell lines were performed as described previously.13 (link) Moreover, a second cytotoxicity assay was performed on only the isolated compounds using the HT-2928 human colorectal adenocarcinoma (HTB-38, ATCC) and the MDA-MB-43529 (link) human melanoma (HTB-129, ATCC) cell lines. All cells were propagated in RPMI 1640 medium supplemented with fetal bovine serum (10%), penicillin (100 units/mL), and streptomycin (100 μg/mL). Cells were plated at either 2,500 (HT-29) or 5,000 (MCF-7, MDA-MB-435) cells per well in 96-well microtiter plates and incubated for 16 h in a humidified, 5% CO2 atmosphere at 37 °C. Test substance was then added at the following final concentrations: 25, 5, 1, 0.2 and 0.04 μg/mL. After a 72-hour incubation, an MTS (3-(4,5-dimethylthiazol-2-yl)-5-(3- carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium, inner salt) assay was performed using a commercially available kit according to the manufacturer’s instructions (CellTiter 96 AQueous One Solution Cell Proliferation Assay, Promega Corp).
Ayers S., Graf T.N., Adcock A.F., Kroll D.J., Matthew S., Carcache de Blanco E.J., Shen Q., Swanson S.M., Wani M.C., Pearce C.J, & Oberlies N.H. (2011). Resorcylic Acid Lactones with Cytotoxic and NF-κB Inhibitory Activities and Their Structure-activity Relationships. Journal of natural products, 74(5), 1126-1131.
Publication 2011
Adenocarcinoma Astrocytoma Atmosphere Biological Assay Carcinoma, Large Cell Cell Lines Cell Proliferation Cells Cytotoxin Fetal Bovine Serum Homo sapiens HT29 Cells Lung Malignant Neoplasms Mammary Carcinoma, Human Melanoma Penicillins Promega Salts Streptomycin Tetrazolium Salts Therapeutics

Most recents protocols related to «Carcinoma, Large Cell»

1
Lung Cancer Patient Clinicopathological Profiles
Patients' clinicopathological profiles, including tumor stage by TNM classification (43 (link)) were presented in Table I and further details were presented in Table SI. The study population consisted of 199 patients according to the following inclusion criteria; those with lung cancer, without history of malignant tumor nor history of other malignant tumor, who had undergone surgery at the Saitama Medical Center at Jichi Medical University (Saitama, Japan) from January 2017 to Jul 2019. These patients included of 142 AC, 45 squamous cell carcinoma (SCC), 4 large cell carcinoma (LCC), 4 small cell carcinoma (SmCC) and 4 pleomorphic carcinoma cases. Serum and urine were collected from 198 healthy individuals (Table SII), whose ages (range, 38–75 years old; mean, 67.5 years old) and sex (127 males and 71 females) were matched as closely as possible with the patients with lung cancer (range, 32–93 years old; mean, 69.3 years old; 128 males and 71 females). Patients or healthy individuals were excluded from the study if they had a history of malignancy, pre-operative chemotherapy and/or diabetes mellitus. Individuals with a Helicobacter pylori infection were also excluded from the study as this infection has been reported to enhance sTFF levels (35 (link)).
All patients and healthy individuals were confirmed to have normal urinary creatinine levels, and all uTFFs were normalized to urinary creatinine to avoid variations in urinary protein concentration.
Minegishi K., Dobashi Y., Koyama T., Ishibashi Y., Furuya M., Tsubochi H., Ohmoto Y., Yasuda T, & Nomura S. (2023). Diagnostic utility of trefoil factor families for the early detection of lung cancer and their correlation with tissue expression. Oncology Letters, 25(4), 139.
Publication 2023
Carcinoma Carcinoma, Large Cell Carcinoma, Small Cell Creatinine Diabetes Mellitus Females Helicobacter pylori Infection Lung Cancer Males Malignant Neoplasms Neoplasms Operative Surgical Procedures Patients Pharmacotherapy Serum Squamous Cell Carcinoma Urine
2
Characterization of Lung Cancer Cell Lines
Details of culture for the following cells lines are provided at protocols.io (dx.doi.org/10.17504/protocols.io.rm7vz82o8vx1/v2). Lung adenocarcinomas: A549 (RRID : CVCL_0023, American Type Culture Collection, ATCC), NCI-H322 (RRID : CVCL_1556, Sigma Aldrich), NCI-H522 (RRID : CVCL_1567, UNKOWN); large cell lung carcinoma: NCI-H460 (RRID : CVCL_0459, ATCC); chronic myelogenous leukemia line, K562 (RRID : CVCL_0004); and the NK-like cell line NK-92 (RRID : CVCL_2142). All cell lines were routinely checked for mycoplasma infection.
Kennedy P.R., Vallera D.A., Ettestad B., Hallstrom C., Kodal B., Todhunter D.A., Bendzick L., Hinderlie P., Walker J.T., Pulkrabek B., Pastan I., Kratzke R.A., Fujioka N., Miller J.S, & Felices M. (2023). A tri-specific killer engager against mesothelin targets NK cells towards lung cancer. Frontiers in Immunology, 14, 1060905.
Full text: Click here
Publication 2023
Adenocarcinoma of Lung Carcinoma, Large Cell Cell Lines Leukemias, Chronic Granulocytic Lung Mycoplasma Infections
3
Prognostic Value of Lymph Node Retrieval in NSCLC
TNM classification was performed according to the criteria of the 8th edition staging of the TNM classification. The cohort was limited to surgical patients at stage IIA NSCLC diagnosed between 2004 and 2015. At the same time, histological type was limited to adenocarcinoma, squamous cell carcinoma, adenosquamous cell carcinoma and large cell carcinoma. Patients with incomplete information or who did not meet the requirements of surgery, pathologic specimen, cancer-specific survival (CSS) (Figure 1) were excluded. The number of RLNs removed was divided into three categories: none RLN removed group, tumor size, RLNs removed 1 to 3 RLNs removed group and greater than or equal to 4 RLNs removed.
Li X., Li G., Wang Y., Tan M, & Wang C. (2023). Removing different number of regional lymph nodes affects survival outcomes of operable patients at stage IIA non-small cell lung cancer (according to the 8th edition staging). Journal of Thoracic Disease, 15(2), 552-567.
Publication 2023
Adenocarcinoma Adenosquamous Carcinoma Carcinoma, Large Cell Cells Malignant Neoplasms Neoplasms Non-Small Cell Lung Carcinoma Operative Surgical Procedures Patients Squamous Cell Carcinoma
4
Comparison of VATS Segmentectomy and Lobectomy for pT1c pN0 NSCLC
We conducted a retrospective multicentre observational study reviewing all consecutive patients with pT1c pN0 NSCLC who underwent a planned complete (R0) VATS segmentectomy (VS) or VATS lobectomy (VL) with lymphadenectomy between January 2014 and October 2021. Patients were treated by 1 of the 5 board-certified thoracic surgeons in 4 different centres across Switzerland. All surgeons had a large experience in VATS anatomical resections. The study population included patients aged over 18 years who underwent VS or VL with mediastinal lymphadenectomy for pT1c pN0 NSCLC (adenocarcinoma, squamous cell carcinoma, large cell carcinoma) only. Eligible patients had to have no history of ipsilateral thoracotomy, no previous chemotherapy or radiotherapy. All patients received contrast-enhanced thoracic CT and a fluorodeoxyglucose-positron emission tomography CT within 30 days prior to the surgery. All tumours had a consolidation-to-tumour ratio of 0.5 or more. Exclusion criteria encompassed all other types of anatomical or extra-anatomical lung resections (wedge, bilobectomy, sleeve lobectomy, pneumonectomy), middle lobectomy, open procedures, synchronous tumour, histology different than previously cited (carcinoid tumour, small-cell lung carcinoma, minimally invasive adenocarcinoma), an 8th edition TNM stage different than pT1c pN0 R0, pleural invasion, multiple lesions, nodal involvement or incomplete resections. Two groups were defined according to the extension of the resection: VL or VS.
Forster C., Abdelnour-Berchtold E., Bédat B., Perentes J.Y., Zellweger M., Sauvain M.O., Christodoulou M., Triponez F., Karenovics W., Krueger T, & Gonzalez M. (2023). Local control and short-term outcomes after video-assisted thoracoscopic surgery segmentectomy versus lobectomy for pT1c pN0 non-small-cell lung cancer. Interdisciplinary Cardiovascular and Thoracic Surgery, 36(2), ivad037.
Full text: Click here
Publication 2023
Adenocarcinoma Carcinoid Tumor Carcinoma, Large Cell F18, Fluorodeoxyglucose Lung Lymph Node Excision Mediastinum Neoplasms Neoplasms, Multiple Primary Non-Small Cell Lung Carcinoma Operative Surgical Procedures Patients Pharmacotherapy Pleura Pneumonectomy Positron-Emission Tomography Radiotherapy Segmental Mastectomy Small Cell Lung Carcinoma Squamous Cell Carcinoma Surgeons Thoracic Surgery, Video-Assisted Thoracotomy
5
Plasma Biomarkers for Lung Cancer
A total of 987 patients admitted to Xinqiao hospital of the Army Medical University from 2014 to 2017 were enrolled in this study. Fasting plasma samples were obtained from 485 patients with NSCLC (including 291 patients with adenocarcinoma, 180 patients with squamous cell carcinoma, 10 patients with adenosquamous carcinoma, and 4 patients with large cell carcinoma), 48 patients with SCLC, and 454 controls. All Lung cancer patients were diagnosed according to NCCN guidelines (15 (link)). The TNM stage of disease was defined according to the 7th edition of the International Association for the Study of Lung Cancer classification system. All lung cancer patients were newly diagnosed and pathologically confirmed by surgical samples or biopsy tissue. Patients who had received surgery, radiotherapy, chemotherapy or targeted drug or had a history of heart, liver, kidney disease, or diabetes were excluded.
The healthy individuals and patients with benign lung diseases were selected as the control group. Healthy controls were recruited from the participants of routine physical examinations during the same period. The benign lung disease group included patients with chronic obstructive pulmonary disease (COPD), pneumonia, pulmonary tuberculosis, and other diseases (pulmonary embolism, bronchiectasis, interstitial lung disease, etc.). Demographic and clinicopathological characteristics of all participants were obtained through a combination of structured questionnaire and medical records. All blood samples were collected after the informed consent of the patients and the study was approved by the ethical committee of the Army Medical University. For each participant, 5ml blood samples were collected and were separated by centrifugation at 4°C and stored in sterile tubes at -80°C within 4 hours of sample collection without repeated freezing and thawing.
Xu Y., Zhang W., Xia T., Liu Y., Bi Z., Guo L., Xie W., Xiang Y., Xu Z., Yu Z., Li Y, & Bai L. (2023). Diagnostic value of tumor-associated autoantibodies panel in combination with traditional tumor markers for lung cancer. Frontiers in Oncology, 13, 1022331.
Full text: Click here
Publication 2023
Adenocarcinoma Adenosquamous Carcinoma Biopsy BLOOD Bronchiectasis Carcinoma, Large Cell Centrifugation Chronic Obstructive Airway Disease Diabetes Mellitus Drug Delivery Systems Heart Kidney Diseases Liver Lung Cancer Lung Diseases Lung Diseases, Interstitial Non-Small Cell Lung Carcinoma Operative Surgical Procedures Patients Pharmacotherapy Physical Examination Plasma Pneumonia Pulmonary Embolism Radiotherapy Small Cell Lung Carcinoma Specimen Collection Squamous Cell Carcinoma Sterility, Reproductive Tissues Tuberculosis, Pulmonary

Top products related to «Carcinoma, Large Cell»

1
Fetal bovine serum (fbs) by Thermo Fisher Scientific
Sourced in United States, China, United Kingdom, Germany, Australia, Japan, Canada, Italy, France, Switzerland, New Zealand, Brazil, Belgium, India, Spain, Israel, Austria, Poland, Ireland, Sweden, Macao, Netherlands, Denmark, Cameroon, Singapore, Portugal, Argentina, Holy See (Vatican City State), Morocco, Uruguay, Mexico, Thailand, Sao Tome and Principe, Hungary, Panama, Hong Kong, Norway, United Arab Emirates, Czechia, Russian Federation, Chile, Moldova, Republic of, Gabon, Palestine, State of, Saudi Arabia, Senegal
Fetal Bovine Serum (FBS) is a cell culture supplement derived from the blood of bovine fetuses. FBS provides a source of proteins, growth factors, and other components that support the growth and maintenance of various cell types in in vitro cell culture applications.
2
Rpmi 1640 medium by Thermo Fisher Scientific
Sourced in United States, China, Germany, United Kingdom, Japan, France, Canada, Australia, Italy, Switzerland, Belgium, New Zealand, Spain, Israel, Sweden, Denmark, Macao, Brazil, Ireland, India, Austria, Netherlands, Holy See (Vatican City State), Poland, Norway, Cameroon, Hong Kong, Morocco, Singapore, Thailand, Argentina, Taiwan, Province of China, Palestine, State of, Finland, Colombia, United Arab Emirates
RPMI 1640 medium is a commonly used cell culture medium developed at Roswell Park Memorial Institute. It is a balanced salt solution that provides essential nutrients, vitamins, and amino acids to support the growth and maintenance of a variety of cell types in vitro.
3
Nci h460 by American Type Culture Collection
Sourced in United States, China, Germany
NCI-H460 is a cell line derived from a human large cell lung carcinoma. It is commonly used in research for the study of lung cancer.
4
Rpmi 1640 by Thermo Fisher Scientific
Sourced in United States, China, United Kingdom, Germany, France, Canada, Japan, Australia, Italy, Switzerland, Belgium, New Zealand, Austria, Netherlands, Israel, Sweden, Denmark, India, Ireland, Spain, Brazil, Norway, Argentina, Macao, Poland, Holy See (Vatican City State), Mexico, Hong Kong, Portugal, Cameroon
RPMI 1640 is a common cell culture medium used for the in vitro cultivation of a variety of cells, including human and animal cells. It provides a balanced salt solution and a source of essential nutrients and growth factors to support cell growth and proliferation.
5
Dulbecco modified eagle medium (dmem) by Thermo Fisher Scientific
Sourced in United States, China, United Kingdom, Germany, France, Australia, Canada, Japan, Italy, Switzerland, Belgium, Austria, Spain, Israel, New Zealand, Ireland, Denmark, India, Poland, Sweden, Argentina, Netherlands, Brazil, Macao, Singapore, Sao Tome and Principe, Cameroon, Hong Kong, Portugal, Morocco, Hungary, Finland, Puerto Rico, Holy See (Vatican City State), Gabon, Bulgaria, Norway, Jamaica
DMEM (Dulbecco's Modified Eagle's Medium) is a cell culture medium formulated to support the growth and maintenance of a variety of cell types, including mammalian cells. It provides essential nutrients, amino acids, vitamins, and other components necessary for cell proliferation and survival in an in vitro environment.
6
Penicillin streptomycin by Thermo Fisher Scientific
Sourced in United States, Germany, United Kingdom, China, Canada, France, Japan, Australia, Switzerland, Israel, Italy, Belgium, Austria, Spain, Gabon, Ireland, New Zealand, Sweden, Netherlands, Denmark, Brazil, Macao, India, Singapore, Poland, Argentina, Cameroon, Uruguay, Morocco, Panama, Colombia, Holy See (Vatican City State), Hungary, Norway, Portugal, Mexico, Thailand, Palestine, State of, Finland, Moldova, Republic of, Jamaica, Czechia
Penicillin/streptomycin is a commonly used antibiotic solution for cell culture applications. It contains a combination of penicillin and streptomycin, which are broad-spectrum antibiotics that inhibit the growth of both Gram-positive and Gram-negative bacteria.
7
H1975 by American Type Culture Collection
Sourced in United States, Japan, Germany, China, France
The H1975 is a laboratory equipment product offered by American Type Culture Collection. It is a specialized device designed for cell culture-related applications. The core function of the H1975 is to provide a controlled environment for the cultivation and maintenance of various cell lines.
8
H1299 by American Type Culture Collection
Sourced in United States, China, United Kingdom, Germany
The H1299 is a cell line derived from a human non-small cell lung carcinoma. It is commonly used in biological research applications.
9
Fetal bovine serum (fbs) by Merck Group
Sourced in United States, Germany, United Kingdom, Japan, Italy, China, Macao, Switzerland, France, Canada, Sao Tome and Principe, Spain, Australia, Ireland, Poland, Belgium, Denmark, India, Sweden, Israel, Austria, Brazil, Czechia, Netherlands, Portugal, Norway, Holy See (Vatican City State), New Zealand, Hungary, Senegal, Argentina, Thailand, Singapore, Ukraine, Mexico
FBS, or Fetal Bovine Serum, is a commonly used cell culture supplement. It is derived from the blood of bovine fetuses and provides essential growth factors, hormones, and other nutrients to support the growth and proliferation of a wide range of cell types in vitro.
10
Nci h1299 by American Type Culture Collection
Sourced in United States, United Kingdom, China, Germany
The NCI-H1299 is a cell line derived from a non-small cell lung carcinoma. It is a widely used model for cancer research.

More about "Carcinoma, Large Cell"

Carcinoma, Large Cell (CLC) is an aggressive form of non-small cell lung cancer (NSCLC) characterized by large, undifferentiated cells with abundant cytoplasm and vesicular nuclei.
This subtype can arise de novo or transform from other NSCLC subtypes.
CLC is a challenging condition that requires prompt diagnosis and appropriate treatment for managing the disease and improving patient outcomes.
Researchers studying CLC often utilize cell lines like NCI-H460, H1975, and H1299 to model the disease.
These cell lines are typically cultured in media such as RPMI 1640 and DMEM, often supplemented with Penicillin/Streptomycin, to support cell growth and proliferation.
Understanding the unique characteristics of CLC and the tools used to study it can inform more effective research strategies.
The power of AI-driven protocol optimization, as offered by PubCompare.ai, can be a game-changer for CLC research.
This innovative tool helps researchers quickly locate the most relevant protocols from literature, pre-prints, and patents, while leveraging AI comparisons to identify the best protocols and products.
By enhancing research accuracy and streamlining workflows, PubCompare.ai can contribute to more efficient and impactful CLC studies.
Synonyms for Carcinoma, Large Cell include Large Cell Carcinoma (LCC) and Large Cell Lung Cancer (LCLC).
Related terms include Non-Small Cell Lung Cancer (NSCLC), Lung Neoplasms, and Carcinoma.
Abbreviations commonly used include CLC, LCC, and LCLC.
Key subtopics in CLC research include tumor biology, genetic alterations, therapeutic targets, and clinical management.